Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9774779 | 0.88 | KMT2A (0.65) | EPHX2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL4016121 | 0.84 | EPHX2 (0.76) | EPHX2 | |
| SCHEMBL2729525 | 0.84 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL27006611 | 0.83 | KMT2A (0.60) | EPHX2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL23696619 | 0.83 | EPHX2 (0.60) | EPHX2KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL4997641 | 0.82 | EPHX2 (0.73) | EPHX2KMT2AALDH1A1DRD2DRD4 | |
| SCHEMBL19000803 | 0.82 | EPHX2 (0.60) | EPHX2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL19000793 | 0.81 | EPHX2 (0.77) | EPHX2MAPTALDH1A1 | |
| SCHEMBL10043041 | 0.81 | KMT2A (1.00) | EPHX2KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL22634120 | 0.80 | KDM4E (0.64) | KMT2AMEN1MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114379-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | NR2E3, DRD2, HCRTR1 | EPHX2 2419/4885KMT2A 1479/4885MEN1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.